You are here:

sevelamer carbonate (Renvela)

Advice

 following an abbreviated submission:

sevelamer carbonate (Renvela®) is accepted for restricted use within NHS Scotland.

Indication under review: control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease.

SMC restriction: the second-line management of hyperphosphataemia in patients receiving haemodialysis.

SMC has previously accepted sevelamer carbonate for restricted use in the second-line management of hyperphosphataemia in adult patients receiving haemodialysis.

Drug Details

Drug Name: sevelamer carbonate (Renvela)
SMC Drug ID: 1304/18
Manufacturer: Sanofi
Indication: Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease.
BNF Category:
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 12 February 2018

Back